Related references
Note: Only part of the references are listed.Alzheimer's Association Report 2011 Alzheimer's disease facts and figures
ALZHEIMERS & DEMENTIA (2011)
Revision of the criteria for Alzheimer's disease: A symposium
Steven T. DeKosky et al.
Alzheimers & Dementia (2011)
Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
Paul S. Aisen et al.
ARCHIVES OF MEDICAL SCIENCE (2011)
A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease
David S. Geldmacher et al.
ARCHIVES OF NEUROLOGY (2011)
Genetics of Alzheimer's disease: new evidences for an old hypothesis?
Jean-Charles Lambert et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease
Angela Gonzalez-Martinez et al.
EXPERIMENTAL GERONTOLOGY (2011)
Drug delivery strategies for Alzheimer's disease treatment
Antonio Di Stefano et al.
EXPERT OPINION ON DRUG DELIVERY (2011)
Memantine in dementia: a review of the current evidence
Nathan Herrmann et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (vol 7, pg 483, 2008)
G. K. Wilcock et al.
LANCET NEUROLOGY (2011)
Alzheimer's disease: clinical trials and drug development (vol 9, pg 702, 2010)
F. Mangialasche et al.
LANCET NEUROLOGY (2011)
A phase II trial of huperzine A in mild to moderate Alzheimer disease
M. S. Rafii et al.
NEUROLOGY (2011)
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Ronald S. Black et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2010)
Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study
Taro Goto et al.
Alzheimers & Dementia (2010)
Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related Disorders
Louis A. Profenno et al.
BIOLOGICAL PSYCHIATRY (2010)
A Meta-Analysis of Cytokines in Alzheimer's Disease
Walter Swardfager et al.
BIOLOGICAL PSYCHIATRY (2010)
Rivastigmine Transdermal Patch Skin Tolerability Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease
Jeffrey L. Cummings et al.
CLINICAL DRUG INVESTIGATION (2010)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Effectiveness and Tolerability of High-Dose (23 mg/d) Versus Standard-Dose (10 mg/d) Donepezil in Moderate to Severe Alzheimer's Disease: A 24-Week, Randomized, Double-Blind Study
Martin R. Farlow et al.
CLINICAL THERAPEUTICS (2010)
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer's Disease
Jaclyn Cappell et al.
CNS DRUGS (2010)
Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease
Murat Emre et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
High PIB Retention in Alzheimer's Disease is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters
A. Forsberg et al.
CURRENT ALZHEIMER RESEARCH (2010)
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Michael Gold et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2010)
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy
P. J. Modrego et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease
Nazem Bassil et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease A Randomized Trial
Joseph F. Quinn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Metabolic Syndrome and Risk of Dementia in Older Adults
Paola Forti et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Harald Hampel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The clinical use of structural MRI in Alzheimer disease
Giovanni B. Frisoni et al.
NATURE REVIEWS NEUROLOGY (2010)
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe
H. H. Feldman et al.
NEUROLOGY (2010)
Alzheimer's disease: clinical trials and drug development
Francesca Mangialasche et al.
LANCET NEUROLOGY (2010)
Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin
Kiren Ubhi et al.
ACTA NEUROPATHOLOGICA (2009)
NIC5-15 as a treatment for Alzheimer's: Safety, pharmacokinetics and clinical variables
Hillel Grossman et al.
Alzheimers & Dementia (2009)
Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men
Pamela Garzone et al.
Alzheimers & Dementia (2009)
Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers
Holly Soares et al.
Alzheimers & Dementia (2009)
The ADCS valproate neuroprotection trial: Primary efficacy and safety results
Pierre N. Tariot et al.
Alzheimers & Dementia (2009)
GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease
Steven Jacobsen et al.
Alzheimers & Dementia (2009)
Donepezil in Severe Alzheimer's Disease
Bengt Winblad
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS (2009)
Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial)
Clive Ballard et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2009)
A γ-Secretase Inhibitor Decreases Amyloid-β Production in the Central Nervous System
Randall J. Bateman et al.
ANNALS OF NEUROLOGY (2009)
Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors A Population-Based Cohort Study
Sudeep S. Gill et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Methylene blue and Alzheimer's disease
Murat Oz et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models
Shun Shimohama
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimer's Disease
Nazem Bassil et al.
CNS DRUGS (2009)
Natural Non-Trasgenic Animal Models for Research in Alzheimer's Disease
Manuel Sarasa et al.
CURRENT ALZHEIMER RESEARCH (2009)
Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
I. A. Lockhart et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2009)
Memantine in Moderately-Severe-to-Severe Alzheimer's Disease A Postmarketing Surveillance Study
Francesca Clerici et al.
DRUGS & AGING (2009)
Cerebrolysin A Review of its Use in Dementia
Greg L. Plosker et al.
DRUGS & AGING (2009)
Cholesterol-modifying strategies for Alzheimer's disease
Alina Solomon et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2009)
Reassessing the amyloid cascade hypothesis of Alzheimer's disease
Sanjay W. Pimplikar
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease A Randomized Controlled Trial
Robert C. Green et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?
Pierre N. Tariot et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Lithium Trial in Alzheimer's Disease: A Randomized, Single-Blind, Placebo-Controlled, Multicenter 10-Week Study
Harald Hampel et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Green Tea (-)-Epigallocatechin-3-Gallate Inhibits β-Amyloid-Induced Cognitive Dysfunction through Modification of Secretase Activity via Inhibition of ERK and NF-κB Pathways in Mice
Jae Woong Lee et al.
JOURNAL OF NUTRITION (2009)
Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase study
D. Saumier et al.
JOURNAL OF NUTRITION HEALTH & AGING (2009)
DEVELOPMENT OF AFFITOPE VACCINES FOR ALZHEIMER'S DISEASE (AD) - FROM CONCEPT TO CLINICAL TESTING
A. Schneeberger et al.
JOURNAL OF NUTRITION HEALTH & AGING (2009)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008)
L. Lannfelt et al.
LANCET NEUROLOGY (2009)
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Norman R. Relkin et al.
NEUROBIOLOGY OF AGING (2009)
Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta
John S. K. Kauwe et al.
NEUROGENETICS (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study
Laura Y. Park-Wyllie et al.
PLOS MEDICINE (2009)
P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Eric R. Siemers et al.
Alzheimers & Dementia (2008)
P4-351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months
Diamanto Tsakanikas et al.
Alzheimers & Dementia (2008)
O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks
Claude M. Wischik et al.
Alzheimers & Dementia (2008)
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline
Parminder Raina et al.
ANNALS OF INTERNAL MEDICINE (2008)
Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis
Ian D. Maidment et al.
ANNALS OF PHARMACOTHERAPY (2008)
Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease
Adam S. Fleisher et al.
ARCHIVES OF NEUROLOGY (2008)
Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice
Kavon Rezai-Zadeh et al.
BRAIN RESEARCH (2008)
The role of peroxisome proliferator-activated receptor-gamma (PPAR gamma) in Alzheimer's disease
Qingguang Jiang et al.
CNS DRUGS (2008)
Peroxisome proliferator-activated receptor-γ-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status
William T. Festuccia et al.
ENDOCRINOLOGY (2008)
Emerging and potential therapies for Alzheimer's disease
Heledd H. Griffiths et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing
M. Marcade et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Volumetric MRI and cognitive measures in Alzheimer disease - Comparison of markers of progression
Basil H. Ridha et al.
JOURNAL OF NEUROLOGY (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
Rachelle S. Doody et al.
LANCET (2008)
Evaluation of Dimebon in cellular model of Huntington's disease
Jun Wu et al.
MOLECULAR NEURODEGENERATION (2008)
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Ganesh M. Shankar et al.
NATURE MEDICINE (2008)
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology
Z. Arvanitakis et al.
NEUROLOGY (2008)
Tau-based treatment strategies in neurodegenerative diseases
Anja Schneider et al.
NEUROTHERAPEUTICS (2008)
PPARγ agonists as therapeutics for the treatment of Alzheimer's disease
Gary Landreth et al.
NEUROTHERAPEUTICS (2008)
No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial
Danielle de Jong et al.
PLOS ONE (2008)
The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae
Camilla A. Hansson Petersen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease
P. Hemachandra Reddy et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease:: a phase IIa, double-blind, randomised, placebo-controlled trial
Lars Lannfelt et al.
LANCET NEUROLOGY (2008)
Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity
Roberto Cappai et al.
NEUROCHEMICAL RESEARCH (2008)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Gordon K. Wilcock et al.
LANCET NEUROLOGY (2008)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (vol 7, pg 483, 2008)
[Anonymous]
LANCET NEUROLOGY (2008)
Galantamine in Alzheimer’s disease
George Razay et al.
Expert Review of Neurotherapeutics (2007)
Donepezil for the treatment of agitation in Alzheimer's disease
Robert J. Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals
Douglas R. Galasko et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2007)
Forecasting the global burden of Alzheimer's disease
Ron Brookmeyer et al.
ALZHEIMERS & DEMENTIA (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease
Z.-H. Wei et al.
JOURNAL OF NEURAL TRANSMISSION (2007)
Donepezil: an update
Ben Seltzer
EXPERT OPINION ON PHARMACOTHERAPY (2007)
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
Patrick L. McGeer et al.
NEUROBIOLOGY OF AGING (2007)
Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
Chang Yi Wang et al.
VACCINE (2007)
Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment
Suzanne Craft
CURRENT ALZHEIMER RESEARCH (2007)
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease
Keith D. Coon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Francine Gervais et al.
NEUROBIOLOGY OF AGING (2007)
Effects of Cerebrolysin™ on neurogenesis in an APP transgenic model of Alzheimer's disease
Edward Rockenstein et al.
ACTA NEUROPATHOLOGICA (2007)
Soluble protein oligomers in neurodegeneration:: lessons from the Alzheimer's amyloid β-peptide
Christian Haass et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Memantine (Ebixa®) in clinical practice -: Results of an observational study
Pasquale Calabrese et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
Current state and future directions of neurochemical biomarkers for Alzheimer's disease
Dankille de Jong et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2007)
Functional outcomes of drug treatment in Alzheimer's disease - A systematic review and meta-analysis
Richard A. Hansen et al.
DRUGS & AGING (2007)
Meta-analysis of six-month memantine trials in Alzheimer's disease
Rachelle Smith Doody et al.
ALZHEIMERS & DEMENTIA (2007)
Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials
Bengt Winblad et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
P. S. Aisen et al.
NEUROLOGY (2006)
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
Katharina Buerger et al.
BRAIN (2006)
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease - The Framingham heart study
Ernst J. Schaefer et al.
ARCHIVES OF NEUROLOGY (2006)
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Henry Engler et al.
BRAIN (2006)
ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease:: OmegAD study -: A randomized double-blind trial
Yvonne Freund-Levi et al.
ARCHIVES OF NEUROLOGY (2006)
Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial
Elaine R. Peskind et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2006)
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Randall J. Bateman et al.
NATURE MEDICINE (2006)
Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40
Samir Kumar-Singh et al.
HUMAN MUTATION (2006)
Cerebrolysin decreases amyloid-β production by regulating amyloid protein precursor maturation in a Transgenic model of Alzheimer's disease
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease
Agneta Nordberg
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2006)
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
ER Siemers et al.
NEUROLOGY (2006)
Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity
S Bastianetto et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine
Gary L. Wenk et al.
BEHAVIOURAL PHARMACOLOGY (2006)
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial
D. L. Sparks et al.
ACTA NEUROLOGICA SCANDINAVICA (2006)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
H Kaduszkiewicz et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
R Bullock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice
MT Heneka et al.
BRAIN (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Effects of memantine on behavioural symptoms in Alzheimer's disease patients:: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
S Gauthier et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2005)
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease - FDG-PET studies in MCI and AD
L Mosconi
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis
RDJ Harry et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2005)
Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period
S Lopez-Pousa et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2005)
Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: Results of a meta-analysis
MR Farlow et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2005)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial
PN Tariot et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Rofecoxib - No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study
SA Reines et al.
NEUROLOGY (2004)
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
RC Dodel et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice
R Etcheberrigaray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
C Holmes et al.
NEUROLOGY (2004)
Metaanalysis of randomized trials of the efficacy and safety of Donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease
CW Ritchie et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2004)
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting
E Aguglia et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review
CA Szekely et al.
NEUROEPIDEMIOLOGY (2004)
Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site -: Evidence for an allosteric mechanism
D Beher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
RW Jones et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2004)
Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle
S Pakrasi et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2003)
Alzheimer's disease-affected brain:: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
YS Gong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity
S Weggen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons
Y Takada et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
JL Eriksen et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease
MC Morris et al.
ARCHIVES OF NEUROLOGY (2003)
Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between notch S3 and β-APP cleavages
HD Lewis et al.
BIOCHEMISTRY (2003)
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial
PS Aisen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory
PR Turner et al.
PROGRESS IN NEUROBIOLOGY (2003)
Memantine in moderate-to-severe Alzheimer's disease
B Reisberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D Strozyk et al.
NEUROLOGY (2003)
The role of insulin resistance in the pathogenesis of Alzheimer's disease - Implications for treatment
GS Watson et al.
CNS DRUGS (2003)
A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease
G Wilcock et al.
DRUGS & AGING (2003)
Selective inhibition of Aβ42 production by NSAID R-enantiomers
T Morihara et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias - Review and comparison of the cholinesterase inhibitors
DB Hogan et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2002)
The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia:: Implications for Alzheimer's disease
JJM Hoozemans et al.
BRAIN RESEARCH (2002)
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease:: A 26-week randomized, placebo-controlled, double-blind trial
M Simons et al.
ANNALS OF NEUROLOGY (2002)
Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people
K Rockwood et al.
ARCHIVES OF NEUROLOGY (2002)
The green tea polyphenol (-)-epigallocatechin gallate attenuates β-amyloid-induced neurotoxicity in cultured hippocampal neurons
YT Choi et al.
LIFE SCIENCES (2001)
Amyloid β-peptide promotes permeability transition pore in brain mitochondria
PI Moreira et al.
BIOSCIENCE REPORTS (2001)
A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease
LM Refolo et al.
NEUROBIOLOGY OF DISEASE (2001)
Implication of APP secretases in notch signaling
D Hartmann et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2001)
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
J Lewis et al.
SCIENCE (2001)
In-vivo measurement of activated microglia in dementia
A Cagnin et al.
LANCET (2001)
Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study
WA Van Gool et al.
LANCET (2001)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
K Fassbender et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single-chain antibody
D Frenkel et al.
JOURNAL OF NEUROIMMUNOLOGY (2000)
Alzheimer-related τ-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia
DR Thal et al.
EXPERIMENTAL NEUROLOGY (2000)
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats
T Kosasa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
A randomized controlled trial of prednisone in Alzheimer's disease
PS Aisen et al.
NEUROLOGY (2000)
Share Paper
